Catriona Yale - Sep 13, 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Development Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Sep 13, 2022
Transactions value $
-$1,099,228
Form type
4
Date filed
9/15/2022, 07:59 PM
Previous filing
Sep 13, 2022
Next filing
Oct 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Sale -$707K -26K -21.31% $27.18 96.1K Sep 13, 2022 Direct F1, F2
transaction AKRO Common Stock Sale -$392K -14K -14.56% $28.04 82.1K Sep 13, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated October 8, 2020, as amended on June 11, 2021, previously adopted by the reporting person.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $26.74 to $27.50, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.98 to $28.235, inclusive.